Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10395855" target="_blank" >RIV/00064165:_____/19:10395855 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/19:10395855

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=v6QXyLmewd" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=v6QXyLmewd</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00059-017-4645-3" target="_blank" >10.1007/s00059-017-4645-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy

Popis výsledku v původním jazyce

Background: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. Patients and methods: We examined plasma OPN as well as creatinine, C-reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. Results: Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 +- 43 vs. 57 +- 21 ng/ml; p &lt; 0.001) and control subjects (54 +- 19 ng/ml; p &lt; 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p &lt; 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p &lt; 0.001 for BNP, CRP, and NYHA, respectively). Conclusion: Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.

Název v anglickém jazyce

Plasma osteopontin levels in patients with dilated and hypertrophic cardiomyopathy

Popis výsledku anglicky

Background: Osteopontin (OPN) is an extracellular matrix glycoprotein that plays a role in a variety of cellular activities associated with inflammatory and fibrotic responses. Increased OPN levels in myocardium and plasma have been demonstrated in patients with dilated cardiomyopathy (DCM). However, nothing is known about OPN levels in patients with hypertrophic cardiomyopathy (HCM). Therefore, the aim of our study was to compare plasma OPN levels in patients with these two most common cardiomyopathies. Patients and methods: We examined plasma OPN as well as creatinine, C-reactive protein (CRP), brain-type natriuretic peptide (BNP), and troponin I levels in 64 patients with DCM, 43 patients with HCM, and 75 control subjects. Transthoracic echocardiography was also performed on all cardiomyopathy patients. Results: Plasma OPN levels were significantly elevated in patients with DCM compared with HCM patients (95 +- 43 vs. 57 +- 21 ng/ml; p &lt; 0.001) and control subjects (54 +- 19 ng/ml; p &lt; 0.001); however, there was no difference between HCM patients and control subjects. New York Heart Association (NYHA) class III or IV disease was more frequently present in DCM patients than in HCM subjects (44 % vs. 2 %, p &lt; 0.0001). In multivariate analysis, BNP and CRP levels together with NYHA class were found to be significant predictors of plasma OPN levels in DCM patients (p = 0.002, p = 0.029, and p &lt; 0.001 for BNP, CRP, and NYHA, respectively). Conclusion: Plasma OPN levels were associated with overall heart failure severity rather than with specific cardiomyopathy subtype in patients suffering from DCM or HCM, respectively.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Herz

ISSN

0340-9937

e-ISSN

—

Svazek periodika

44

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

347-353

Kód UT WoS článku

000471606200010

EID výsledku v databázi Scopus

2-s2.0-85034265053